Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

25-10-2019(Fri) 24-10-2019(Thu) 23-10-2019(Wed) 22-10-2019(Tue) 21-10-2019(Mon)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
23 Sep, 2019 (Monday)

            
MODERN DENTAL(3600)
Analysis¡G
Modern Dental Group (3600) focuses on providing custom-made prostheses to customers in the growing prosthetics industry. Its product portfolio is broadly categorised into three product lines: (i) fixed prosthetic devices; (ii) removable prosthetic devices; and (iii) others such as orthodontic devices, sports guards and anti-snoring devices, raw materials, dental equipment and the services of educational events and seminars rendered. The aging population has a direct impact on the demand for dental prosthetic devices. With new production facilities in Dongguan, the Group expects to further consolidate its status in Greater China market as it would have sufficient room to expand its production capacity significantly. (I do not hold the above stock)
Strategy¡G
Buy-in Price: $1.45, Target Price: $1.60, Cut Loss Price: $1.35


CSPC PHARMA(1093)
Analysis¡G
After more than 20 years of development, CSPC has successfully transformed from the most important raw material drug manufacturer in China into a high-tech enterprise led by innovative brand drugs. The innovative medicines of CSPC are mainly aimed at cardiovascular and anti-tumor. In the field, the company has high marketing efficiency, large investment in R&D, and leading in per capita output and R&D. In 2019H, revenue increased by 27.6% to 11.2 billion yuan, of which the growth of innovative drugs was rapid (+55.4%), gross profit margin increased by 6pts to 69.9%, and net profit increased by 24.8%.
Strategy¡G
Buy-in Price: $14.90, Target Price: $16.00, Cut Loss Price: $12.60


Japan Medical Dynamic Marketing, Inc. (7600)
Established in 1973. Handles the import, development, manufacture and retail of medical equipment focusing on the field of orthopaedic surgery. The U.S. Ortho Development Corporation (ODEV) acquired in 1994 carries out the development and manufacture of osteosynthetic material, prosthetic joints and spinal fixation apparatuses and supplies them to the company, in addition, they also carry out the retail of prosthetic joints and spinal fixation apparatuses in the U.S. For 1Q (Apr-Jun) results of FY2020/3 announced on 31/7, net sales increased by 16.0% to 4.364 billion yen compared to the same period the previous year, operating income increased by 41.1% to 646 million yen and net income increased by 41.7% to 448 million yen. Despite carrying out insurance reimbursement price cuts in phases in April, sales in the fields of prosthetic joints, osteosynthetic material and spinal fixation apparatuses have become steady. For its full year plan, net sales is expected to increase by 8.8% to 18.2 billion yen compared to the previous year, operating income to increase by 10.1% to 2.46 billion yen, and net income to decrease by 13.3% to 1.72 billion yen. Revised their 1H company plan upwards on 28/8. Net sales have been raised from 8.2 billion yen to 8.65 billion yen, and operating income from 820 million yen to 1.17 billion yen. A possible upturn for the full year as well.



China Southern Airlines(1055.HK) - 2019H Result: Slightly Lower Revenue Growth than Expected, and Sound Control of Cost

Investment Summary

Earnings Decreased by 20% by Year in H1

In 2019H1, the revenue of CSA was RMB72.94 billion, an increase of 7.97% yoy, the net profit attributable to the parent company was RMB1.69 billion, a decrease of 20.92% yoy, and the net profit excluding non-recurring items was RMB1.43 billion, a decrease of 22% yoy.

In 2019 Q1 and Q2 the revenue of the Company reached RMB37.63 billion and 35.31 billion, respectively, an increase of 10.4% and 5.54% yoy, while the net profit attributable to the parent company was +RMB2.65 billion in Q1, an increase of 4.1%, and -RMB960 million in Q2, an increase of RMB550 million in loss.

Yield of Domestic Routes under Pressure in Q2

The trade friction between China and the United States have intensified, and the domestic macroeconomic downturn resulted in a sluggish growth in aviation demand. The fare level during the off-season (especially of domestic routes) was under pressure. Though the overall P L /F increased by 0.2 ppts yoy to 82.65%, the unit revenue per passenger kilometre dropped by 1.65% yoy to RMB0.478. The P L /F of domestic routes dropped by 0.12 ppts, and the yield level dropped by 1.52% yoy to RMB0.518. The P L /F of international routes increased by 0.84 ppts, and the yield level of the same dropped by 0.79%, while the P L /F of regional routes increased by 1.96 ppts, and the yield level of the same dropped by 1.21%.

Slightly Lower Revenue Growth than Expected, and Sound Control of Cost

In H1, the total revenue of the Company increased by 7.97% yoy to RMB72.94 billion, while the growth rate decreased by 4 ppts when compared to that of the corresponding period. In addition to the pressured demand, the suspension of Boeing 737MAX and the total quantity control of the Civil Aviation Administration also brought a drag on the Company's capacity release. The available seat kilometre increased by 10.14% yoy, which was below expectations and a decrease of 2 ppts, approx., when compared to that of the corresponding period. As a result, the passenger turnover growth decreased by 1.9 ppts yoy to 10.3%.

During the period, the Company continued to strengthen its control on major costs and optimize its flight operation mechanism, and the cost was saved effectively. The operating cost increased by 7.2% yoy, less than the increase in total revenue. The unit available ton kilometre cost decreased by 1.62% yoy to RMB2.846.

Financial Expense Increased Significantly Due to Changes in Accounting Standards

The financial expense reached RMB3,243 million, an increase of RMB1,207 million or 59% yoy, of which, the net exchange loss reached RMB312 million, a decrease of 25.7% when compared to that of the same period of last year. The interest expense excluding those capitalized was RMB2,876 million, a significant increase of RMB1.34 billion or 87% yoy, mainly due to the implementation of new lease rules and the rise of interest expense on lease liabilities. Meanwhile, due to the new lease rules, the total assets of CSA increased by 21.7% to RMB300,171 million from that at the beginning of the period, the total liabilities increased by 33.18% to RMB224,378 million from that at the beginning of the period, the ratio of USD liabilities increased by 16 ppts from that at the end of 2018, and the sensitivity of net profit to USD exchange rate increased from RMB195 million to RMB517 million.

Investment Thesis

In Q3, as the industry prosperity is basically flat with that of the previous year, it is expected that the redeployment of capacity will boost the operating efficiency of the domestic routes of the Company to a certain extent, while that of international routes will remain the same. In H2, the halving of the levy on the civil aviation fund will help reduce the cost, though the RMB exchange rate and oil price trend in the short term will be the most significant risk factors for performance.

In accordance with the latest data, we adjust the estimate of the Company's EPS to RMB0.35/0.57 in 2019/2020. The target price is HK$ 6, equivalent to 15.4/9.5x and 0.96/0.88x estimated P/E ratio and P/B ratio, respectively, in 2019/2020. The "Buy" rating is maintaining. (Closing price as at 19 September)

Risk

Traffic demand languished for the deterioration of macro-economy;

The depreciation of the RMB against USD would bring exchange loss;

Oil prices rose exceeded forecast.

War, terrorist attacks, SARS and other emergencies;

Irrational inter-industrial price war;

Financials

Click Here for PDF format...




Recommendation on 23-9-2019
RecommendationBUY
Price on Recommendation Date$ 4.850
Suggested purchase priceN/A
Target Price$ 6.000
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2019 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]